Biotech Visionaries Venter, Hariri and Diamandis Unite on MYOS Board of Directors
MYOS Corporation announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors. The “three musketeers of innovation,” J. Craig Venter, Ph.D., Robert J. Hariri, M.D., Ph.D. and Peter Diamandis, M.D. have united prior to MYOS as co-founders of Human Longevity, Inc., a genomics and cell therapy-based diagnostic and therapeutic company. Now, the three join forces again on the MYOS Board of Directors to help advance the MYOS team in developing treatments for age-related muscle loss, sarcopenia, and cachexia.
"It is my great pleasure to welcome Craig to the MYOS Board," commented Dr. Hariri. "Craig is regarded as one of the most highly distinguished and innovative scientists of the 21st century. His numerous invaluable contributions to genomic research are legendary. Craig and I have known each other for many years and share a common interest and deep passion for furthering scientific understanding of the building blocks of life and identifying meaningful therapeutic options to address aging-related human biological decline. Craig has not only led a revolution in biomedicine which has reshaped our knowledge of the processes central to all life, but has inspired a generation of scientists, myself included, to challenge the convention in the pursuit of a deeper understanding of those mechanisms responsible for disease. MYOS is extremely fortunate to have the most important scientist in genomics, synthetic biology and human longevity join us as we strive to build a leading company dedicated to muscle health."
Click here to read the full press announcement and join us in welcoming Dr. Venter to MYOS!